Kevin P. P. Mahoney

Dr. Kevin P. P. Mahoney

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2014 in Synthesis
Verified
Journal Article
Closed access
PDF file
RGRebecca Goss
Rebecca Goss
KMKevin P. P. Mahoney
Kevin P. P. Mahoney
DSDuncan R. M. Smith
Duncan R. M. Smith
EBEmma J. A. Bogosyan
Emma J. A. Bogosyan
Access to natural products and their analogues is crucial. Such compounds have, for many years, played a central role in the area of drug discovery as well as in providing tools for chemical biology­. The ability to quickly and inexpensively acquire genome sequences has accelerated the field of natural product research. Access to genomic data coupled with new technologies for the engineering of organisms is resulting in the identification of large numbers of previously undiscovered natural products as well as an increased understanding of how the biosynthetic pathways responsible for the biogenesis of these compounds may be manipulated. This short review summarizes and reflects upon approaches to accessing natural products and has a particular focus on approaches combining molecular biology and synthetic chemistry. 1 Introduction 2 CHEM: Total Synthesis 3 BIO-CHEM: Semi-Synthesis 4 CHEM-BIO: Precursor Directed Biosynthesis 5 BIO-CHEM-BIO: Mutasynthesis 6 BIO-BIO: Combinatorial Biosynthesis 7 BIO-BIO-CHEM: Genochemetics: Gene Expression Enabling Synthetic Diversification 8 Conclusions and Future Directions in Natural Product Analogue Generation

19 June 2025 in Biomolecules
Verified
Journal Article
Open access
KMKevin P. P. Mahoney
Kevin P. P. Mahoney
RLRosemary Lynch
Rosemary Lynch
RBRhea T. Bown
Rhea T. Bown
SSSunil Sharma
Sunil Sharma
PCPiyasiri Chueakwon
Piyasiri Chueakwon
RGRebecca Goss
Rebecca Goss
Pharmaceuticals, such as the antibiotic erythromycin, and sodium-dependent glucose transporter (SGLT1 & SGTL2) inhibitors such as Bexagliflozin (diabetes) and Sotagliflozin (heart disease), are often sugar-decorated (glycosylated). Glycosylation is a key component of the binding motif in SGLT inhibitors and, in natural products, glycosylation often confers improved bioactivity and bioavailability. Whilst a single C-glycoside link between a sugar moiety and its aglycone core is a common feature in natural products isolated to date, only a small number, including the antibiotics granaticin and sarubicin, are covalently bonded twice to a single sugar moiety. The way in which this “double C-glycosylation” is naturally mediated is not yet known, yet has been speculated on. Here, we report the exploration and development of a potentially biomimetic procedure that utilises intermolecular cycloaddition chemistry to access new “double C-glycosylated” products and enables the creation of bridged polycyclic ethers from a common maltol-derived oxidopyrylium salt precursor.